Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
Experts at the NAMD Fall Conference discussed challenges with high-cost drugs.
Letter ·
NAMD Highlights Concerns with Proposed Pharmacy Value-Based Purchasing Rule
On July 20, 2020, NAMD submitted comments to the Centers for Medicare and Medicaid Services on a proposed rule seeking to promote value-based purchasing in pharmaceuticals.
The proposed rule would allow pharmaceutical manufacturers to report multiple “best prices” under the Medicaid Drug Rebate Program unique to specific value-based purchasing arrangements. In the letter, NAMD expresses concern that this would undermine state pharmacy budgets and create strong incentives for pharmaceutical manufacturers to game the “best price.”
Related resources
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence...
State Associations Request Removal of EVV GPS Ban from 21st Century Cures Act Successor Legislation
NAMD joined our sister state associations in requesting that lawmakers remove a proposed ban on the use of...
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.